Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Although FDA did not approve the biosimilar for pediatric ulcerative colitis, Inflectra labeling states that a pediatric assessment demonstrates it is 'safe and effective in another pediatric indication.'